Ivermectin Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Adjunct / Ancillary Health

Adjunct / Ancillary Health compound Tablet verified

Also known as: 22,23-dihydroavermectin B1a, 22,23-dihydroavermectin B1b, H2B1a, H2B1b, CAS 70288-86-7

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes
3 mg tablet, 6 mg tablet
Components
Ivermectin B1a (at least 90%) + Ivermectin B1b (less than 10%)
Storage
Follow product label or prescribing information; not independently verified for this entry.
Solubility
Formulation dependent; follow supplier/prescribing information.

Blend Components

This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.

Component
Ivermectin B1a (at least 90%)
Calculator Profile
Component
Ivermectin B1b (less than 10%)
Calculator Profile
Open All in Blend Calculator

Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.

Catalog Description

Ivermectin is a semisynthetic broad-spectrum antiparasitic agent derived from avermectins produced by Streptomyces avermitilis. FDA-labeled oral tablet indications include intestinal strongyloidiasis caused by Strongyloides stercoralis and onchocerciasis caused by Onchocerca volvulus. It acts primarily on invertebrate glutamate-gated chloride channels, producing hyperpolarization and paralysis of susceptible parasites. The drug has no activity against adult Onchocerca volvulus parasites. Ivermectin has not been FDA-approved for prevention or treatment of COVID-19.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
18 hours
Onset
Not independently established for this entry; see cited half-life for pharmacokinetic context.
Administration Routes (Research)
Oral

Reported Research Effects

Reported Research Side Effects

Data source: Compiled pharmacology reference (community + literature ranges)

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Route-Specific Research Protocols

Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.

Label / guideline Human study Community only Preclinical only Not established
Oral Community only

0.2 mg/kg, as needed per prescribing guidance

Technique
Oral
Evidence
Literature / community-reported range

Context: Dose figures reflect ranges commonly cited in performance/clinical literature and community reports, not a recommended protocol. This compound is typically prescription-only or requires medical supervision; entry is provided as a pharmacology reference only.

Formulation: Route-specific formulation and handling requirements apply.

Route safety: Reference range only. Do not treat as an individualized or clinically established protocol.

Source status: No direct community citation is attached to this amount.

Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.

Research Notes

This record is a pharmacology and reference entry, not a treatment protocol. FDA-labeled oral tablet information reports approved indications for intestinal strongyloidiasis and onchocerciasis, including reference regimens of a single 200 micrograms/kg dose for intestinal strongyloidiasis and 150 micrograms/kg for onchocerciasis; these are reported label regimens, not personalized dosing advice. Human studies have also evaluated other schedules and routes, but those findings should not be generalized to self-administration or unapproved uses.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN 70288-86-7; PubChem compound record for ivermectin mixture; component empirical formulas C48H74O14 (B1a) and C47H72O14 (B1b).

Source-Backed Observations

Ivermectin is a mixture of closely related avermectin homologs rather than a single discrete molecular species. Human oral tablet labeling describes a plasma half-life of approximately 18 hours, peak plasma concentrations at approximately 4 hours after a single 12 mg dose in fasting healthy volunteers, hepatic metabolism, and predominantly fecal elimination. A high-fat meal increased ivermectin bioavailability in a labeled pharmacokinetic study.

Reflects published research. Educational reference — not a recommendation for use.

Sources

DailyMed: Ivermectin Tablets USP, 3 mg and 6 mg
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fb17bc2-9192-4a0b-a3ee-fda9db035daa (accessed 2026-09-10)
PubChem: Ivermectin
https://pubchem.ncbi.nlm.nih.gov/compound/Ivomec (accessed 2026-09-10)
FDA: Ivermectin and COVID-19
https://www.fda.gov/consumers/consumer-updates/ivermectin-and-covid-19 (accessed 2026-09-10)
Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18 mg tablet in healthy adult volunteers
https://pubmed.ncbi.nlm.nih.gov/29346388/ (accessed 2026-09-10)
Determination of ivermectin in human plasma by high-performance liquid chromatography
https://pubmed.ncbi.nlm.nih.gov/8329009/ (accessed 2026-09-10)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Blend CalculatorPre-filled with all blend components Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top